Three rearrangements of chromosome 5 in a patient with myelodysplastic syndrome: an atypical deletion 5q, a complex intrachromosomal rearrangement of chromosome 5, and a paracentric inversion of chromosome 5

Douet‐Guilbert, Nathalie; Basinko, Audrey; Eveillard, Jean‐Richard; Morel, Frédéric; Bris, Marie‐Josée Le; Guéganic, Nadia; Bovo, Clément; Herry, Angèle; Berthou, Christian; Braekeleer, Marc De

doi:10.1016/j.cancergencyto.2010.07.129

Cited by 5 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An unusual case of MDS with a paracentric inv(5)(q15q33) as the only observed abnormality was recently reported in a patient undergoing routine quarterly monitoring; this patient did not require treatment [ 19 ]. Another patient was previously described having complex intrachromosomal rearrangements of chromosome 5, including a paracentric inversion [ 20 ]. In this case, the chromosome 5 rearrangements progressively evolved into three sequential clones.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A treatment-refractory aggressive MDS-MLD with multiple highly complex chromosome 5 intrachromosomal rearrangements: a case report

et al. 2022

View full text Add to dashboard Cite

Background A patient with a myelodysplastic neoplasm exhibited a karyotype with multiple complex chromosome 5 rearrangements. This patient appeared to have a catastrophic cytogenetic event that manifested as a treatment-refractory aggressive form of disease, which lead to patient demise within one year. Both the clinical presentation and disease course were unusual based on the medical history and morphologic findings. Such cases of myelodysplastic syndrome with multilineage dysplasia (MDS-MLD) with complex abnormalities are not reported in the literature. Case presentation The patient was a 62-year-old female who presented with pancytopenia and dyspnea. The morphologic appearance of the peripheral blood smear and bone marrow biopsy, along with flow cytometric findings, favored the diagnosis of MDS-MLD unclassifiable. Myelodysplastic syndrome (MDS) with multilineage dysplasia (MDS-MLD), is an MDS characterized by one or more cytopenias and dysplastic changes in two or more of the myeloid lineages (i.e., erythroid, granulocytic, and megakaryocytic). The bone marrow, in particular, showed prominent dysplasia, including the presence of atypical megakaryocytes with small hypolobated morphology reminiscent of those typically seen in MDS with isolated 5q deletion. Cytogenetic analysis, including interphase and metaphase FISH, karyotype and SNP chromosomal microarray were performed, as well as DNA sequencing studies. Cytogenetic analysis showed a very complex karyotype featuring multiple 5q intrachromosomal rearrangements including a pericentric inversion with multiple interspersed deletions and monosomy 7. FISH studies showed a partial deletion of the PDGFRβ gene, and SNP chromosomal microarray and targeted panel-based sequencing identified biallelic loss of function of the TP53 gene. Based on the pathologic findings, the patient was treated for MDS but did not respond to either lenalidomide or azacitidine. Conclusion The genetic changes described, in particular, the complex intrachromosomal rearrangements of chromosome 5, suggest the occurrence of a sudden catastrophic event that led to an aggressive course in the patient’s disease. Conventional karyotyping, metaphase and interphase FISH, SNP chromosomal microarray and NGS helped to identify the complex genetic changes seen in this case. This highlights the importance of utilizing a multimodality approach to fully characterize complex chromosomal events that may significantly impact disease progression, treatment and survival.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In this case, the chromosome 5 rearrangements progressively evolved into three sequential clones. This patient had an initial good response to lenalidomide, but treatment was stopped after a year due to adverse effects with subsequent disease progression and the disease advanced to RAEB-2 within 6 months [ 20 ].…”

Section: Discussionmentioning

confidence: 99%